Cubist Pharmaceuticals, Inc. Patent applications |
Patent application number | Title | Published |
20150306076 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 10-29-2015 |
20150025053 | CEPHALOSPORIN COMPOUND - The cephalosporin compound of formula (I) is disclosed, which exhibits antibiotic activity against Gram-negative (e.g., | 01-22-2015 |
20140371135 | HIGH PURITY LIPOPEPTIDES - The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of | 12-18-2014 |
20140364380 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 12-11-2014 |
20140274998 | CEFTOLOZANE-TAZOBACTAM PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam. | 09-18-2014 |
20140163048 | COMPOSITIONS WITH INCREASED STABILITY FOR INHIBITING TRANSIENT RECEPTOR POTENTIAL ION CHANNEL TRPA1 - This disclosure describes solid forms of the compound of Formula (I) and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain. | 06-12-2014 |
20140158116 | INHIBITING TRPA1 FOR THE TREATMENT OF ASTHMA - This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as asthma. | 06-12-2014 |
20140135273 | CB-183,314 COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel solid CB-183,315 formulations which have improved chemical stability. The chemical stability of the solid CB-183,315 is dependent on the process by which the composition is made. Solid preparations of CB-183,315 can be prepared by the following method: (a) forming an aqueous solution of CB-183,315 and at least one sugar that (e.g., sucrose, trehalose or dextran) at a pH of 2-7, preferably pH 6 and (b) converting the aqueous solution to the solid preparation of CB-183,315 (e.g., via lyophilization or spray drying). | 05-15-2014 |
20140088067 | TAZOBACTAM ARGININE COMPOSITIONS - This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions. | 03-27-2014 |
20140087425 | METHODS FOR PREPARING PURIFIED LIPOPEPTIDES - The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions. | 03-27-2014 |
20140073559 | Antibiotic Compositions for the Treatment of Gram Negative Infections - Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds. | 03-13-2014 |
20140073558 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS - The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against | 03-13-2014 |
20130274273 | Inhibiting Transient Receptor Potential Ion Channel TRPA1 - This disclosure describes a novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain. | 10-17-2013 |
20130109633 | CB-183,315 Compositions and Related Methods | 05-02-2013 |
20130065874 | METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane. | 03-14-2013 |
20120270772 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 10-25-2012 |
20090155234 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, MX1 - A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided. | 06-18-2009 |
20080318267 | Methods and Compositions for Ultra-High Throughput Screening of Natural Products - The present invention provides cells having more than two drug resistance genes and at least two different resistance genes that have been recombined into the chromosome of a cell. It also teaches the processes for preparing cells by recombining two or more different drug resistance genes into the chromosome of a cell. The invention further shows a screening method using the cells of described herein that may be used to accomplish high throughput screening of, among other things, natural products and/or whole cells isolated from the environment. | 12-25-2008 |
20080213366 | Therapeutic Compositions - The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described. | 09-04-2008 |